Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Ivana Gojo, MD, Robert K. Stuart, MD, Jonathan Webster, MD, Amanda Blackford, MS, Juan Carlos Varela, MD PhD, Jillian Morrow, RN, Amy E. DeZern, MD, Matthew C Foster, MD, Mark J. Levis, MD, Catherine C. Coombs, MD, Gabrielle T. Prince, MD, B. Douglas Smith, MD, Hendrik W. Van Deventer, MD, Katarzyna Jamieson, MD, Ravi Varadhan, PhD, Benjamin G. Vincent, MD, Jonathan S Serody, MD, Leo Luznik, MD, Joshua F Zeidner, MD

Blood (2019) 134 (Supplement_1): 832.

https://doi.org/10.1182/blood-2019-127345

Published: 2019

Journal Articles

Altered Expression of Neddylation Pathway Proteins in Myelodysplastic Syndromes

Fatemeh Majidi, MD, Judith Neukirchen, MD, Simon Brille, Iris Fey, BSc., Frank Neumann, MDPhD, Allison Berger, PhD, Ron-Patrick Cadeddu, PhD, Martina Rudelius, MD, Ulrich Germing, MD, Rainer Haas, MD, Norbert Gattermann, MD

Blood (2017) 130 (Supplement 1): 5298.

https://doi.org/10.1182/blood.V130.Suppl_1.5298.5298

Published: 2017

Journal Articles

Efficacy and Safety of Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Patients Aged ≥75 Years with Acute Myeloid Leukemia (AML) in the Phase 3 AZA-AML-001 Study

John F. Seymour, MD, Rena Buckstein, MD, Valeria Santini, MD, Hartmut Döhner, MD, Richard M. Stone, MD, Mark D. Minden, MD PhD, Ching-Yuan Kuo, MD, Dina Ben-Yehuda, MD, Joan Bargay, MD, Stephen Songer, PharmD, Jerry Weaver, PhD, C.L. Beach, PharmD, Hervé Dombret, Prof.

Blood (2016) 128 (22): 2818.

https://doi.org/10.1182/blood.V128.22.2818.2818

Published: 2016

Journal Articles

Tracking Effector T Cell Dynamics and Immune Inhibitory Receptors in Patients with Acute Myeloid Leukemia (AML)

Hanna A. Knaus, MD, Raúl Montiel-Esparza, MD, Joshua F. Zeidner, MD, Amanda Blackford, ScM, Christopher G. Kanakry, MD, Ante Vulic, MD, Mark J. Levis, MD PhD, Judith E. Karp, MD, Leo Luznik, MD, Ivana Gojo, MD

Blood (2015) 126 (23): 3849.

https://doi.org/10.1182/blood.V126.23.3849.3849

Published: 2015

Journal Articles

Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007

Graça M. Dores, Susan S. Devesa, Rochelle E. Curtis, Martha S. Linet, Lindsay M. Morton

Blood (2012) 119 (1): 34–43.

https://doi.org/10.1182/blood-2011-04-347872

Published: 2012

Includes: Supplemental data

Journal Articles

Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases

Porcia T. Bradford, Susan S. Devesa, William F. Anderson, Jorge R. Toro

Blood (2009) 113 (21): 5064–5073.

https://doi.org/10.1182/blood-2008-10-184168

Published: 2009

Journal Articles

A novel apoptosis pathway activated by the carboxyl terminus of p21

Chen Dong, Qing Li, Shu-chen Lyu, Alan M. Krensky, Carol Clayberger

Blood (2005) 105 (3): 1187–1194.

https://doi.org/10.1182/blood-2004-06-2188

Published: 2005

NARROW

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Altered Expression of Neddylation Pathway Proteins in Myelodysplastic Syndromes

Efficacy and Safety of Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Patients Aged ≥75 Years with Acute Myeloid Leukemia (AML) in the Phase 3 AZA-AML-001 Study

Tracking Effector T Cell Dynamics and Immune Inhibitory Receptors in Patients with Acute Myeloid Leukemia (AML)

Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007

Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases

A novel apoptosis pathway activated by the carboxyl terminus of p21

Email alerts

ASH Publications

American Society of Hematology

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Altered Expression of Neddylation Pathway Proteins in Myelodysplastic Syndromes

Efficacy and Safety of Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Patients Aged ≥75 Years with Acute Myeloid Leukemia (AML) in the Phase 3 AZA-AML-001 Study

Tracking Effector T Cell Dynamics and Immune Inhibitory Receptors in Patients with Acute Myeloid Leukemia (AML)

Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007

Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases

A novel apoptosis pathway activated by the carboxyl terminus of p21

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only